Press release
Investigation for Investors in shares of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) over potential Wrongdoing announced
An investigation on behalf of investors in Fulcrum Therapeutics, Inc. (NASDAQ: FULC) shares over potential wrongdoing.
Investors who purchased shares of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain Fulcrum Therapeutics, Inc. directors breached their fiduciary duties and caused damage to the company and its shareholders.
Cambridge, MA based Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. On July 17, 2019, Fulcrum Therapeutics, Inc announced the pricing of its initial public offering ("IPO") of 4.5 million shares at $16.00 per share, for gross proceeds of $72.0 million.
However, since the IPO shares of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) declined to $6.27 per share on October 3, 2019.
Those who purchased shares of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) have certain options and should contact the Shareholders Foundation.
Media Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Investigation for Investors in shares of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) over potential Wrongdoing announced here
News-ID: 2036841 • Views: …
More Releases from Shareholders Foundation
ALERT: Lawsuit filed for Investors who SOLD shares of Sina Corporation (formerly …
An investor, who sold shares of Sina Corporation (formerly NASDAQ: SINA) in the merger between Seina Corporation and TuSimple Holdings, Inc, filed a lawsuit over alleged violations of Federal Securities Laws by Sina Corporation (formerly NASDAQ: SINA in connection with certain allegedly false and misleading statements made.
If you sold a significant amount of shares of Sina Corporation (formerly NASDAQ: SINA) between October 13, 2020 and March 22, 2021, you have…
Lawsuit Alert: Investors who lost money with shares of Fluor Corporation (NYSE: …
An investor, who purchased shares of Fluor Corporation (NYSE: FLR), filed a lawsuit alleged violations of Federal Securities Laws by Fluor Corporation in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Fluor Corporation (NYSE: FLR) have certain options and for certain investors are short and strict deadlines running. Deadline: November 14, 2025. NYSE: FLR investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779…
Investigation announced for Long-Term Investors in shares of Sable Offshore Corp …
An investigation was announced for long-term investors in shares of Sable Offshore Corp. (NYSE: SOC) concerning potential breaches of fiduciary duties by certain directors of Sable Offshore Corp.
Investors who are current long term investors in Sable Offshore Corp. (NYSE: SOC) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in…
Lawsuit filed for Investors who lost money with shares of Lantheus Holdings, Inc …
An investor, who purchased shares of Lantheus Holdings, Inc. (NASDAQ: LNTH), filed a lawsuit over alleged violations of Federal Securities Laws by Lantheus Holdings, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Lantheus Holdings, Inc. (NASDAQ: LNTH) have certain options and for certain investors are short and strict deadlines running. Deadline: November 10, 2025. NASDAQ: LNTH investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
More Releases for Fulcrum
Facioscapulohumeral Muscular Dystrophy Market Anticipated to Expand Rapidly Duri …
DelveInsight's "Facioscapulohumeral Muscular Dystrophy Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Facioscapulohumeral Muscular Dystrophy, historical and forecasted epidemiology as well as the Facioscapulohumeral Muscular Dystrophy market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Facioscapulohumeral Muscular Dystrophy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Facioscapulohumeral Muscular Dystrophy…
Facioscapulohumeral Muscular Dystrophy Market to Show Remarkable Growth Trends f …
The Key Facioscapulohumeral Muscular Dystrophy Companies in the market include - Fulcrum Therapeutics, aTyr Pharma, Fulcrum Therapeutics, Hoffmann-La Roche, Pfizer, Avidity Biosciences, Inc, and others.
DelveInsight's "Facioscapulohumeral Muscular Dystrophy Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Facioscapulohumeral Muscular Dystrophy, historical and forecasted epidemiology as well as the Facioscapulohumeral Muscular Dystrophy market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and…
Census Acquires Fulcrum to Enhance Data Collaboration and Modeling
The strategic acquisition will accelerate Census's roadmap for AI-led customer segmentation, personalization, and data modeling.
San Francisco, CA, USA - July 17, 2024 - Census, the #1 data activation and reverse ETL platform [https://www.getcensus.com/blog/what-is-data-activation], has announced its acquisition of Fulcrum, a AI-led growth platform for business teams.
Image: https://www.getnews.info/uploads/02a46bc0675193e89da14681ac87fa37.jpg
AI-driven insights, operations, and agents are the future of how enterprises operate efficiently and impact business growth. Fulcrum and Census will create a foundation…
Facioscapulohumeral Muscular Dystrophy (FSHD) Market Report 2032: Epidemiology D …
DelveInsight's "Facioscapulohumeral Muscular Dystrophy Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Facioscapulohumeral Muscular Dystrophy, historical and forecasted epidemiology as well as the Facioscapulohumeral Muscular Dystrophy market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Facioscapulohumeral Muscular Dystrophy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Facioscapulohumeral Muscular Dystrophy…
Biojet Fuels market: Players tapping Emerging Markets | Neste, Total, Fulcrum Bi …
The Biojet Fuels global market is thoroughly researched in this report, noting important aspects like market competition, global and regional growth, market segmentation and market structure. The report author analysts have estimated the size of the global market in terms of value and volume using the latest research tools and techniques. The report also includes estimates for market share, revenue, production, consumption, gross profit margin, CAGR, and other key factors.…
Investigation announced for Investors in shares of Fulcrum Therapeutics, Inc. (N …
Fulcrum Therapeutics, Inc. is under investigation over potential securities laws violations in connection with certain financial statements.
Investors who purchased shares of Fulcrum Therapeutics, Inc. (NASDAQ: FULC), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on whether a series of statements by Fulcrum Therapeutics, Inc. regarding its business, its prospects and its operations were materially false…
